



PATENT  
Attorney Docket No. 07675.0001-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of: )  
Christer OWMAN )  
Application No.: 09/893,512 ) Group Art Unit: 1647  
Filed: June 29, 2001 ) Examiner: R. LANDSMAN  
For: HEPTAHELIX RECEPTOR AND )  
ITS USE AS LEUKOTRIENE B4 )  
RECEPTOR )

Assistant Commissioner for Patents  
Washington, D.C. 20231

DECLARATION PURSUANT TO 37 C.F.R. § 1.132

We, Christer Owman and Jesper Bristulf, declare that:

1. We have read and understand the present patent application, including the claims.
2. On information and belief, we previously submitted a Declaration, executed January 20, 2003, in Lund, Sweden, attesting to the fact that the original nucleotide sequence of the Lyme21-9 clone was obtained by Christer Owman, and that the originally-obtained sequence included reading errors that were later corrected by Jesper Bristulf.
3. The Lyme21-9 clone originally sequenced by Christer Owman is the same clone that was later sequenced by Jesper Bristulf.
4. The Lyme21-9 clone sequenced by both Christer Owman and Jesper Bristulf is the same clone originally disclosed in the present application.
5. The Lyme 21-9 clone sequenced by both Christer Owman and Jesper Bristulf is the same clone that was deposited at the ATCC, which was assigned Accession No. PTA-4543.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.400.4000  
Fax 202.400.4400  
www.finnegan.com

TECH CENTER 1600/2000

APR 09 2003

RECEIVED

Attorney Docket No. 07675.0001-03  
Application No. 09/893,512

6. All statements made herein of my knowledge are true. All statements made herein on information and belief are believed to be true. All statements made herein were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements might jeopardize the validity of this application or any patent issuing therefrom.

Date:

April 7, 2003

By:



Christer Owman, Ph.D., M.D.

Date:

7/4-2003

By:



Jesper Bristulf, Ph.D.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



PATENT  
Attorney Docket No. 07675.0001-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of: )  
Christer OWMAN )  
Application No.: 09/893,512 )  
Filed: June 29, 2001 )  
For: HEPTAHELIX RECEPTOR AND )  
ITS USE AS LEUKOTRIENE B4 )  
RECEPTOR )

Group Art Unit: 1647

Examiner: R. LANDSMAN

Assistant Commissioner for Patents  
Washington, D.C. 20231

DECLARATION PURSUANT TO 37 C.F.R. § 1.804

I, Bjorn Olde, declare that:

1. I am a citizen of Sweden, residing at Vastergaten 6, SE-222, 29 Lund, Sweden.
2. I have read and understand the present U.S. patent application, including the claims.
3. I have been professionally associated with Dr. Christer Owman, the inventor and applicant for this application, since October, 1994.
4. On information and belief, the Lyme21-9 clone disclosed in the present application, as originally filed, has been deposited at the ATCC, and assigned Accession No. PTA-4543.
5. The Lyme21-9 clone originally disclosed in the present application, as filed, is the same biological material that was deposited at the ATCC.

TECH CENTER 1600/2900

APR 09 2003

RECEIVED

Attorney Docket No. 07675.0001-03  
Application No. 09/893,512

6. All statements made herein of my knowledge are true. All statements made herein on information and belief are believed to be true. All statements made herein were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements might jeopardize the validity of this application or any patent issuing therefrom.

Date:

2003-04-07

By:

  
Bjorn Olde, Ph.D.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNN LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com